-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at RBC Capital
-
-
-
-
-
-
-
Goldman Sachs Starts Jazz Pharmaceuticals (JAZZ) at Buy
-
-
-
-
-
-
-
Ligand Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Catalyst Alert: Phase 3 Results for Xywav in Idiopathic Hypersomnia (IH)
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
-
15,579 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

